Journal of Andrology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published-Ahead-of-Print April 17, 2008, DOI:10.2164/jandrol.108.004952
Journal of Andrology, Vol. 29, No. 5, September/October 2008
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.108.004952

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/5/580    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Resmini, E.
Right arrow Articles by Ferone, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Resmini, E.
Right arrow Articles by Ferone, D.

Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments

EUGENIA RESMINI, GABRIELLA ANDRAGHETTI, ALBERTO REBORA, RENZO CORDERA, LARA VERA, MASSIMO GIUSTI, FRANCESCO MINUTO AND DIEGO FERONE

From the Department of Endocrinology and Medical Sciences and Center of Excellence for Biomedical Research, University of Genova, Italy.

Correspondence to: Dr Eugenia Resmini, Department of Endocrinology and Medical Sciences, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy (e-mail: resminieugenia{at}libero.it).


Gender differences in leptin, ghrelin, and adiponectin levels have been described in a normal population. This is important for understanding differences between males and females in the regulation of food intake, weight gain, body fat distribution, and cardiovascular risk. It is unclear how endogenous and exogenous sex hormones may regulate circulating levels of these factors. Transsexuals during hormonal treatment may represent an ideal model to ascertain the role of exogenous sex hormones on these parameters. In this study, our objective was to evaluate adiponectin, ghrelin, and leptin levels in transsexual subjects during hormone therapy and to compare the results of males and females. Subjects were 26 nondiabetic transsexuals, which included 15 male-to-female (M-to-F, group 3) and 11 female-to-male (F-to-M, group 4) individuals, and 29 age- and BMI-matched controls, which included 15 males (group 1) and 14 females (group 2). Results showed that leptin levels were significantly lower in group 1 compared with group 2 (P = .04) and group 3 (P = .01); no differences were recorded between the other groups. Adiponectin levels were significantly higher in group 3 compared with group 4 (P = .03). No differences were found between the 4 groups for ghrelin levels. In conclusion, our data confirm the sexual dimorphism in serum leptin levels in normal subjects and demonstrate an increase in M-to-F transsexuals. While ghrelin does not show any sexual differences and seems not to be influenced by exogenous sex hormone administration, the lower adiponectin levels in F-to-M transsexuals during treatment confirm that androgens may decrease plasma adiponectin levels. This latter observation suggests that F-to-M transsexual patients could have a higher cardiovascular risk.

     Key words: Cardiovascular risk, sexual hormones, metabolic parameters






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The American Society of Andrology.